Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Tejinder | - |
dc.contributor.author | Kim, Tae Wan | - |
dc.contributor.author | Murthy, Akula S. N. | - |
dc.contributor.author | Paul, Mohuya | - |
dc.contributor.author | Sepay, Nasim | - |
dc.contributor.author | Kong, Hye Jeong | - |
dc.contributor.author | Ryu, Jae Sung | - |
dc.contributor.author | Koo, Na Rim | - |
dc.contributor.author | Yoon, Sujeong | - |
dc.contributor.author | Song, Keon-Hyoung | - |
dc.contributor.author | Baek, Moo Jun | - |
dc.contributor.author | Jeon, Seob | - |
dc.contributor.author | Im, Jungkyun | - |
dc.date.accessioned | 2024-06-11T07:02:33Z | - |
dc.date.available | 2024-06-11T07:02:33Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.issn | 1768-3254 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25951 | - |
dc.description.abstract | Poor intracellular uptake of therapeutics in the tumor parenchyma is a key issue in cancer therapy. We describe a novel approach to enhance tumor targeting and achieve targeted delivery of camptothecin (CPT) based on a tumor-homing internalizing RGD peptide (iRGD). We synthesized an iRGD-camptothecin conjugate (iRGD-CPT) covalently coupled by a heterobifunctional linker and evaluated its in vitro and in vivo activity in human colon cancer cells. In vitro studies revealed that iRGD-CPT penetrated cells efficiently and reduced colon cancer cell viability to a significantly greater extent at micromolar concentrations than did the parent drug. Furthermore, iRGD-CPT showed high distribution toward tumor tissue, effectively suppressed tumor progression, and showed enhanced antitumor effects relative to the parent drug in a mouse model, demonstrating that iRGD-CPT is effective in vivo cancer treatment. These results suggest that intracellular delivery of CPT via the iRGD peptide is a promising drug delivery strategy that will facilitate the development of CPT derivatives and prodrugs with improved efficacy. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | - |
dc.title | Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy | - |
dc.type | Article | - |
dc.publisher.location | 프랑스 | - |
dc.identifier.doi | 10.1016/j.ejmech.2023.116050 | - |
dc.identifier.scopusid | 2-s2.0-85180604441 | - |
dc.identifier.wosid | 001147242400001 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.265 | - |
dc.citation.title | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.citation.volume | 265 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.subject.keywordPlus | ANTICANCER DRUG | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | LIPOSOMES | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | MICELLES | - |
dc.subject.keywordAuthor | Tumor -homing and tumor-penetrating peptide | - |
dc.subject.keywordAuthor | iRGD | - |
dc.subject.keywordAuthor | Drug delivery | - |
dc.subject.keywordAuthor | Camptothecin | - |
dc.subject.keywordAuthor | Colon cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.